HPLC Verified
Research Grade
COA Published
Tirzepatide 15mg
Tirzepatide
CAS: 2023788-19-2
Tirzepatide 15mg — dual GLP-1/GIP receptor agonist. SURMOUNT-1 Phase 3: −20.9% body weight at 72 weeks. Second-generation GLP compound with proven Phase 3 data.
Price
$149.99
45 in stock
HPLC verified · third-party tested · research use only
Specifications
Dual-Agonist: GLP-1R + GIPR
Tirzepatide activates two receptors — GLP-1R and GIPR. GLP-1R drives hypothalamic appetite suppression and delayed gastric emptying. GIPR (Glucose-dependent Insulinotropic Polypeptide Receptor) engagement improves insulin sensitivity and enhances adipocyte lipid metabolism — meaning fat cells become more efficient at releasing stored fat. The addition of GIPR to GLP-1R is mechanistically why tirzepatide consistently outperforms semaglutide in head-to-head data. SURMOUNT-1 Phase 3 (15mg/week, 72 weeks): −20.9% body weight — substantially better than semaglutide's −14.9% and the strongest Phase 3 approval data for any GLP compound. Compared to Retatrutide, tirzepatide lacks GcgR (glucagon receptor) activation — meaning no active hepatic fat oxidation or thermogenesis.
SURMOUNT-1 Phase 3: −20.9% at 72 Weeks
Tirzepatide SURMOUNT-1 (15mg/week): −20.9% body weight at 72 weeks. This is Phase 3 data — large-scale, controlled, peer-reviewed. It represents the strongest approved Phase 3 fat loss data for any GLP compound, providing a robust and well-characterised evidence base.
GIPR Addition — The Dual Mechanism Advantage
GIPR agonism improves insulin sensitivity (more efficient glucose disposal) and enhances adipocyte lipid metabolism (fat cells more readily release stored lipids). The combination of GLP-1R appetite suppression plus GIPR metabolic enhancement is the mechanistic reason tirzepatide consistently produces better results than semaglutide.
Phase 3 Data vs Retatrutide Phase 2
Tirzepatide's −20.9% comes from large Phase 3 trials. Retatrutide's −28.7% comes from smaller Phase 2 data. Phase 3 trials typically produce more conservative results. A direct head-to-head Phase 3 comparison has not been published — interpreting the raw numbers requires accounting for trial design differences.
Frequently Asked Questions
Why does Tirzepatide outperform Semaglutide?
Tirzepatide adds GIPR to GLP-1R agonism. GIPR improves insulin sensitivity and enhances adipocyte lipid metabolism, providing a second fat loss mechanism beyond GLP-1R appetite suppression. SURMOUNT-1 data: −20.9% vs semaglutide's −14.9% — approximately 40% more fat loss from the additional receptor.
How does Tirzepatide compare to Retatrutide?
Retatrutide adds a third receptor (GcgR) to tirzepatide's dual-agonist profile. GcgR drives hepatic beta-oxidation and brown adipose thermogenesis. Retatrutide Phase 2: −28.7%. Tirzepatide Phase 3: −20.9%. Important caveat: Phase 2 data is from smaller trials and is typically more optimistic than Phase 3.
What is the dose escalation for Tirzepatide?
Standard escalation: 2.5mg/week (weeks 1–4) → 5mg/week (weeks 5–8) → 7.5mg/week (weeks 9–12) → 10mg/week (weeks 13–16) → 12.5mg/week (weeks 17–20) → 15mg/week (week 21+). The 15mg vial provides approximately 6 weeks of initiation supply.
Related Products
Semaglutide 3mg
Semaglutide
GLP-1 receptor agonist. 99.1% purity. Starter 3mg vial suited to initial dose-titration research; STEP-1 trial recorded −14.9% mean body weight at 68 weeks.
$49.99
CAS 910463-68-2
Semaglutide 6mg
Semaglutide
GLP-1 receptor agonist. 99.1% purity. Mid-range 6mg vial supports two-vial titration schedules; STEP-1 Phase 3 mean weight reduction −14.9% over 68 weeks.
$79.99
CAS 910463-68-2
Tirzepatide 15mg
$149.99